The statin family of hydroxymethylglutaryl coenzyme A reductase (HMGCR) inhibitors, used to control hypercholesterolemia, triggers apoptosis of various human tumour cells. HMGCR is the rate-limiting enzyme of the mevalonate (MVA) pathway, a fundamental metabolic pathway required for the generation of a number of biochemical end-products including cholesterol and isoprenoids, but the contribution of the MVA pathway to human cancer remains largely unexplored. Furthermore, as only a subset of tumour cells has been shown to be highly responsive to statins, the identification of appropriate subsets of patients will be required to successfully advance these agents as anticancer therapeutics. To this end, there were two major aims to this work: 1) Elucidate a molecular rationale for the observed therapeutic index of statin-induced apoptosis in normal and tumour cells; 2) Identify molecular determinants of sensitivity for statin-induced apoptosis in human tumour cells. To address the first aim we demonstrated that dysregulation of the MVA pathway, achieved by ectopic expression of either full length HMGCR (HMGCR-FL) or its novel splice variant lacking exon 13 (HMGCR-D13), increases transformation. Ectopic HMGCR promotes growth of transformed and non-transformed cells under anchorage-independent conditions or as xenografts in immunocompromised mice. We also show that high mRNA levels of HMGCR and four out of five other MVA pathway genes correlate with poor prognosis in primary breast cancer, suggesting the MVA pathway may play a role in the etiology of human cancers. To address the second aim, we show that dysregulation of the MVA pathway is a key determinant of sensitivity to statin-induced apoptosis in multiple myeloma. In a panel of 17 distinct myeloma cell lines, half were sensitive to statin-induced apoptosis and the remainder were insensitive. Interestingly, in sensitive cells, the classic feedback response to statin exposure is lost, a feature we demonstrated could distinguish a subset of statin-sensitive primary myeloma cells. We further illustrated that statins are highly effective and well tolerated in an orthotopic model of myeloma using cells harboring a dysregulated MVA pathway. Taken together, this work provides a molecular rationale and determinants of sensitivity for statin-induced apoptosis of human tumour cells.

Mémoire numérisé par la Direction des bibliothèques de l'Université de Montréal.

The statin family of hydroxymethylglutaryl coenzyme A reductase (HMGCR) inhibitors, used to control hypercholesterolemia, triggers apoptosis of various human tumour cells. HMGCR is the rate-limiting enzyme of the mevalonate (MVA) pathway, a fundamental metabolic pathway required for the generation of a number of biochemical end-products including cholesterol and isoprenoids, but the contribution of the MVA pathway to human cancer remains largely unexplored. Furthermore, as only a subset of tumour cells has been shown to be highly responsive to statins, the identification of appropriate subsets of patients will be required to successfully advance these agents as anticancer therapeutics. To this end, there were two major aims to this work: 1) Elucidate a molecular rationale for the observed therapeutic index of statin-induced apoptosis in normal and tumour cells; 2) Identify molecular determinants of sensitivity for statin-induced apoptosis in human tumour cells. To address the first aim we demonstrated that dysregulation of the MVA pathway, achieved by ectopic expression of either full length HMGCR (HMGCR-FL) or its novel splice variant lacking exon 13 (HMGCR-D13), increases transformation. Ectopic HMGCR promotes growth of transformed and non-transformed cells under anchorage-independent conditions or as xenografts in immunocompromised mice. We also show that high mRNA levels of HMGCR and four out of five other MVA pathway genes correlate with poor prognosis in primary breast cancer, suggesting the MVA pathway may play a role in the etiology of human cancers. To address the second aim, we show that dysregulation of the MVA pathway is a key determinant of sensitivity to statin-induced apoptosis in multiple myeloma. In a panel of 17 distinct myeloma cell lines, half were sensitive to statin-induced apoptosis and the remainder were insensitive. Interestingly, in sensitive cells, the classic feedback response to statin exposure is lost, a feature we demonstrated could distinguish a subset of statin-sensitive primary myeloma cells. We further illustrated that statins are highly effective and well tolerated in an orthotopic model of myeloma using cells harboring a dysregulated MVA pathway. Taken together, this work provides a molecular rationale and determinants of sensitivity for statin-induced apoptosis of human tumour cells.

The enzyme 3-Hydroxy-3- Methylglutaryl Coenzyme A Reductase catalyzes the rate limiting step of hepatic cholesterol biosynthesis and is unique among the enzymes in the early part of the pathway in that it is membrane bound. This gives rise to potential regulation of the enzyme through interactions with the endoplasmic reticulum membrane. A purification procedure has been developed which consistently produces enzyme of high specific activity. In order to fully characterize the interactions between HMG-CoA reductase and the lipids in its immediate environment, HMG-CoA reductase was purified to homogeneity and shown to be a protein-lipid complex.

No description available.

Mémoire numérisé par la Direction des bibliothèques de l'Université de Montréal. / L'objectif de notre travail est de vérifier l'effet de la réduction du cholestérol sérique sur la mortalité totale dans les études impliquant des diètes ou des inhibiteurs de la HMG-CoA réductase (statines) comme moyens de traitement hypocholestérolémiants, et de traduire cet effet en termes actuariels afin de comparer la mortalité dans ces études avec la mortalité attendue dans la population générale donnée par les tables de mortalité. La méthodologie employée sera décrite avant la revue de la littérature. J Nous avons utilisé les données de trois études de population connues, impliquant des inhibiteurs de la HMG-CoA réductase (4S ou Scandinavian Simvastatin Survival Study, CARE ou Cholesterol And Reçurent Events , WOSCOPS ou West Of Scotland Coronary Prevention Study) et de quatre études impliquant la diète (LRC-CPPT ou Lipid Research Clinic Coronary Primary Prevention Trial, MRFIT ou Multiple Risk Factor Intervention Trial, ODHS ou Oslo Diet Heart Study et LDHS ouLyon Diet Heart Study) pour déterminer l'impact des interventions par la diète ou par prescription des inhibiteurs de la HMG-CoA réductase sur la survie. La méthode actuarielle employée permettra de comparer la mortalité observée dans le groupe placebo et dans le groupe sous intervention à la mortalité prévue (attendue) donnée par les tables de mortalité. Cette méthodologie permettra d'une part de comparer l'espérance de vie du groupe placebo dans tes grandes études de population, avec les données actuarielles. D'autre part, ces données, présentées sur une base actuarielle, permettront de mieux préciser le risque associé à l'hyperlipémie, basé sur des études récentes de population. En prévention primaire: les inhibiteurs de la HMG-CoA réductase réduisent les niveaux de cholestérol élevés et suppriment la mortalité excessive qui leur est reliée (étude WOSCOPS). En cas de multiples facteurs de risque, ta mortalité est comparable à celle des coronariens, mais l'impact des mesures de correction des facteurs de risque sur l'espérance de vie reste modeste (MRFIT). En prévention secondaire, les statines réduisent de presque de moitié le risque de mortalité en cas de cholestérol sérique élevé (étude 4S), cependant cet impact est plus modeste en cas de cholestérolémie normale (étude CARE). Parmi les mesures diététiques, seule la diète méditerranéenne a un effet très marqué en rendant le risque de mortalité chez le coronarien comparable à la population normale (Lyon diet heart study). Notre travail est présenté sous forme de deux articles devant être soumis à la publication dans la revue American Journal Of Insurance Medicine et dans Canadian Dietetic Association Journal. Les deux articles sont précédés d'une revue des principales études épidémiologiques et cliniques sur la relation entre le niveau de cholestérol sérique et la mortalité par maladie coronarienne. Le premier article concerne l'analyse de mortalité dans les études utilisant les diètes, en prévention primaire (MRFIT, LRC-CPPT) et en prévention secondaire (ODHS, LDHS), le second concerne des études impliquant les statines, en prévention primaire (WOSCOPS) et en prévention secondaire (CARE, 4S). Chacun des deux articles comprend une introduction, une analyse des données, les résultats, leur discussion, une conclusion et les références bibliographiques relatives soit à l'intervention par la diète soit par les statines. Une conclusion commune aux deux volets est faite à la fin de cette étude.

Avaliou-se os efeitos dos ácidos oleanólico (AO) e ursólico (AU), triterpenóides presentes em alimentos vegetais e especiarias, quando administrados a ratos F344 durante as etapas de iniciação e seleção/promoção do modelo de hepatocarcinogênese do \"hepatócito resistente\" (RH). Os ratos receberam durante 8 semanas, por entubação gástrica e dissolvido em óleo de milho (OM): AO ou AU (8 mg/100 g de peso corpóreo [p.c.]). Os grupos controle receberam apenas OM (0,25 mL/100 g de p.c; grupo OM), ou água (0,25 mL/100 g de p.c.; grupo Água). O grupo Normal não recebeu qualquer tratamento. O agente iniciante foi uma dose de dietilnitrosamina (DEN, 20 mg/100 g de p.c.). Após 2 semanas de entubação, aplicou-se 3 doses diárias consecutivas de 2-acetilaminofluoreno (2-AAF) (2 mg/100 g de p.c.) e fez-se uma hepatectomia parcial a 70%, acrescida de 1 dose de 2-AAF (0,5 mg/100 g de p.c.) 4 dias após a cirurgia. Em 6 semanas após a iniciação, os animais foram sacrificados. Resultados: A análise macroscópica demonstrou que AO não determinou alterações e AU tendeu a aumentar o número de nódulos de hepatócitos, comparados ao grupo OM. A análise morfométrica das lesões pré-neoplásicas (LPN) hepáticas positivas para glutationa S-transferase forma placentária (GST-p), demonstrou que AO e AU não determinaram alterações no número médio de LPN persistentes, porém reduziram o número médio de LPN em remodelação, comparados ao grupo OM (p < 0,05). AO e AU não determinaram alterações na área média das LPN persistentes, mas diminuíram a área média das LPN em remodelação, comparados ao grupo OM (p < 0,05). AO e AU não determinaram alterações na área do corte ocupada por LPN persistentes, mas diminuíram a área do corte ocupada por LPN em remodelação, comparados ao grupo OM (p < 0,05). Os grupos Água, OM e AU apresentaram aumento na concentração plasmática de colesterol, comparados ao grupo Normal. AO promoveu aumento da expressão do gene que codifica para a enzima HMG-CoA redutase, comparado ao grupo Normal (p < 0,05), e AU promoveu aumento de expressão quando comparado aos grupos Normal, Água, OM e AU (p < 0,05). AO e AU não determinaram alterações nos índices de proliferação celular (imunoistoquímica para bromodeoxiuridina [BrdU]) nas LPN persistentes. AU promoveu aumento (p < 0,05) na proliferação celular nas LPN em remodelação quando comparado ao grupo OM. AO e AU não determinaram alterações na apoptose em LPN persistentes, mas aumentaram o número médio de corpúsculos apoptóticos nas LPN em remodelação (p < 0,05). O índice de Crescimento Ajustado (apoptose/proliferação celular) dos grupos demonstrou que, nas LPN persistentes, a proliferação celular tem predominância sobre a apoptose. Nas LPN em remodelação, a apoptose tem preponderância sobre a proliferação celular. Os danos no DNA hepático (método do \"cometa\") foram maiores no grupo AO (p < 0,05) e AU (p = 0,061), comparados ao grupo OM. A análise por \"imunoblot\" revelou que o modelo do \"RH\" aumentou a expressão e a ativação do fator de transcrição NF-&#954;B (p < 0,05). AO e AU aumentaram a expressão e a ativação de NF-&#954;B, comparados ao grupo OM (p > 0,05). Observou-se que a proteína supressora de tumor p53 está acumulada no citoplasma dos hepatócitos de 77,2% (Água), 66,5% (OM), 69,6% (AO) e 69,7% (AU) das LPN persistentes, e de 22,8% (Água), 33,5% (OM), 30,4% (AO) e 30,3% (AU) das LPN em remodelação marcadas para p53. A proteína anti-apoptótica bcl-2 apresentou aumento de expressão em 78,4% (Água), 72,6% (OM), 73,0% (AO) e 70,4% (AU) das LPN persistentes, e de 21,6% (Água), 27,4% (OM), 27,0% (AO) e 29,6% (AU) das LPN em remodelação marcadas para bcl-2. Conclusões: AO e AU não apresentaram atividade quimiopreventiva nas condições de estudo, mas diminuíram as LPN em remodelação. O aumento da apoptose e diminuição da proliferação celular estão envolvidos com a remodelação. O fator de transcrição NF-&#954;B está envolvido com a hepatocarcinogênese. AO e AU aumentaram a expressão e a ativação de NF-&#954;B. O acúmulo de p53 no citoplasma, bem como a expressão aumentada de bcl-2 estão relacionados ao fenótipo das LPN persistentes. / It was evaluated the effects of the oleanólico acid (OA) and ursolic acid (UA), triterpenoids present in vegetable foods and spices, when administered to rat F344 during the initiation and selection/promotion stages of the resistant hepatocyte model of hepatocarcinogenesis RH. The rat received for 8 weeks, by gavage and dissolved in com oil (CO): OA or UA (8 mg/100 g of body weight [b.w.]). The control groups just received CO (0,25 mL/100 g b.w.; CO group), or water (0,25 mL/100 g b.w.; group Water). Normal group did not receive any treatment type. The initiation agent was dietilnitrosamine (DEN, 20 mg/100 g b.w.). 2 weeks after gavage, it was applied 3 consecutive doses of 2-acetilaminofluoreno (2-AAF) (2 mg/100 g of b.w.) and it was made a 70% partial hepatectomy, added of 1 dose of 2-AAF (0,5 mg/100 9 b.w.) 4 days after the surgery. In 6 weeks after the initiation, the animals were sacrificed. Results: the macroscopic analysis demonstrated that OA did not alter and UA tended to increase the number of hepatocytes nodules, compared to the CO group. The morphometric analysis of the pre-neoplastic lesions (PNL) positive for glutatione S-transferase placentary form (GST-p), demonstrated that OA and UA did not alter the medium number of persistent LPN, however they reduced the medium number of remodeling LPN, compared to the OM group (p <0,05). OA and UA did not alter the medium area of persistent LPN, but they reduced the medium area of remodeling LPN, compared to the CO group (p <0,05). The triterpenoids did not alter the occupied area of the section for persistent LPN, but they reduced the occupied area cut for remodeling LPN, compared to the CO group (p <0,05). The Water, OM and AU groups showed increase in the plasmatic concentration of cholesterol, compared to the Normal group. OA promoted increase of the expression of the gene that codifies for the HMG-CoA reductase enzyme, compared to the Normal group (p <0,05), and AU promoted increase expression when compared to the Normal, Water, OM and AU groups (p <0,05). OA and UA did not alter the indexes of cellular proliferation (imunoistochemistry for bromodeoxiuridine [BrdU)) in persistent LPN. AU promoted increase (p <0,05) in the cellular proliferation in remodeling LPN when compared to the CO group. OA and UA did not alter the apoptosis in persistent LPN, but they increased the medium number of apoptotics bodies in remodeling LPN (p <0,05). The Adjusted Index Growth (cellular apoptosis/proliferation) of the groups demonstrated that, in persistent LPN, the cellular proliferation has predominance on the apoptosis. In remodeling LPN, the apoptosis has preponderance over the cellular proliferation. The damages in hepatic DNA (method of the \"comet\") were larger in the group OA (p <0,05) and AU (p <0,061), compared to the CO group. The analysis for imunoblot revealed that the RH model increased the expression and the activation of the NF-&#954;B transcription factor (p <0,05). OA and UA increased the expression and the activation of NF-&#954;B, compared to the CO group (p> 0,05). It was observed that the p53 tumor suppresser protein is accumulated in the hepatocytes cytoplasm of 77,2% (Water), 66,5% (CO), 69,6% (OA) and 69,7% (UA) of persistent LPN, and of 22,8% (Water), 33,5% (CO), 30,4% (OA) and 30,3% (UA) of remodeling LPN marked for p53. The bcl-2 anti-apoptotic protein presented increase expression in 78,4% (Water), 72,6% (CO), 73,0% (OA) and 70,4% (UA) of persistent LPN, and of 21,6% (Water), 27,4% (CO), 27,0% (OA) and 29,6% (UA) of remodeling LPN marked for bcl-2. Conclusions: AO and AU did not present chemopreventive activity in the study conditions, but they reduced remodeling PNL. The apoptosis increase and cellular proliferation decrease are involved with the remodeling. The transcription factor NF-&#954;B is involved with the hepatocarcinogenesis. AO and AU increased the expression and the activation of NF-&#954;B. The p53 accumulation in the cytoplasm, as well as the increased expression of bcl-2 is related to the phenotype of persistent PNL.

Avaliou-se os efeitos dos ácidos oleanólico (AO) e ursólico (AU), triterpenóides presentes em alimentos vegetais e especiarias, quando administrados a ratos F344 durante as etapas de iniciação e seleção/promoção do modelo de hepatocarcinogênese do \"hepatócito resistente\" (RH). Os ratos receberam durante 8 semanas, por entubação gástrica e dissolvido em óleo de milho (OM): AO ou AU (8 mg/100 g de peso corpóreo [p.c.]). Os grupos controle receberam apenas OM (0,25 mL/100 g de p.c; grupo OM), ou água (0,25 mL/100 g de p.c.; grupo Água). O grupo Normal não recebeu qualquer tratamento. O agente iniciante foi uma dose de dietilnitrosamina (DEN, 20 mg/100 g de p.c.). Após 2 semanas de entubação, aplicou-se 3 doses diárias consecutivas de 2-acetilaminofluoreno (2-AAF) (2 mg/100 g de p.c.) e fez-se uma hepatectomia parcial a 70%, acrescida de 1 dose de 2-AAF (0,5 mg/100 g de p.c.) 4 dias após a cirurgia. Em 6 semanas após a iniciação, os animais foram sacrificados. Resultados: A análise macroscópica demonstrou que AO não determinou alterações e AU tendeu a aumentar o número de nódulos de hepatócitos, comparados ao grupo OM. A análise morfométrica das lesões pré-neoplásicas (LPN) hepáticas positivas para glutationa S-transferase forma placentária (GST-p), demonstrou que AO e AU não determinaram alterações no número médio de LPN persistentes, porém reduziram o número médio de LPN em remodelação, comparados ao grupo OM (p < 0,05). AO e AU não determinaram alterações na área média das LPN persistentes, mas diminuíram a área média das LPN em remodelação, comparados ao grupo OM (p < 0,05). AO e AU não determinaram alterações na área do corte ocupada por LPN persistentes, mas diminuíram a área do corte ocupada por LPN em remodelação, comparados ao grupo OM (p < 0,05). Os grupos Água, OM e AU apresentaram aumento na concentração plasmática de colesterol, comparados ao grupo Normal. AO promoveu aumento da expressão do gene que codifica para a enzima HMG-CoA redutase, comparado ao grupo Normal (p < 0,05), e AU promoveu aumento de expressão quando comparado aos grupos Normal, Água, OM e AU (p < 0,05). AO e AU não determinaram alterações nos índices de proliferação celular (imunoistoquímica para bromodeoxiuridina [BrdU]) nas LPN persistentes. AU promoveu aumento (p < 0,05) na proliferação celular nas LPN em remodelação quando comparado ao grupo OM. AO e AU não determinaram alterações na apoptose em LPN persistentes, mas aumentaram o número médio de corpúsculos apoptóticos nas LPN em remodelação (p < 0,05). O índice de Crescimento Ajustado (apoptose/proliferação celular) dos grupos demonstrou que, nas LPN persistentes, a proliferação celular tem predominância sobre a apoptose. Nas LPN em remodelação, a apoptose tem preponderância sobre a proliferação celular. Os danos no DNA hepático (método do \"cometa\") foram maiores no grupo AO (p < 0,05) e AU (p = 0,061), comparados ao grupo OM. A análise por \"imunoblot\" revelou que o modelo do \"RH\" aumentou a expressão e a ativação do fator de transcrição NF-&#954;B (p < 0,05). AO e AU aumentaram a expressão e a ativação de NF-&#954;B, comparados ao grupo OM (p > 0,05). Observou-se que a proteína supressora de tumor p53 está acumulada no citoplasma dos hepatócitos de 77,2% (Água), 66,5% (OM), 69,6% (AO) e 69,7% (AU) das LPN persistentes, e de 22,8% (Água), 33,5% (OM), 30,4% (AO) e 30,3% (AU) das LPN em remodelação marcadas para p53. A proteína anti-apoptótica bcl-2 apresentou aumento de expressão em 78,4% (Água), 72,6% (OM), 73,0% (AO) e 70,4% (AU) das LPN persistentes, e de 21,6% (Água), 27,4% (OM), 27,0% (AO) e 29,6% (AU) das LPN em remodelação marcadas para bcl-2. Conclusões: AO e AU não apresentaram atividade quimiopreventiva nas condições de estudo, mas diminuíram as LPN em remodelação. O aumento da apoptose e diminuição da proliferação celular estão envolvidos com a remodelação. O fator de transcrição NF-&#954;B está envolvido com a hepatocarcinogênese. AO e AU aumentaram a expressão e a ativação de NF-&#954;B. O acúmulo de p53 no citoplasma, bem como a expressão aumentada de bcl-2 estão relacionados ao fenótipo das LPN persistentes. / It was evaluated the effects of the oleanólico acid (OA) and ursolic acid (UA), triterpenoids present in vegetable foods and spices, when administered to rat F344 during the initiation and selection/promotion stages of the resistant hepatocyte model of hepatocarcinogenesis RH. The rat received for 8 weeks, by gavage and dissolved in com oil (CO): OA or UA (8 mg/100 g of body weight [b.w.]). The control groups just received CO (0,25 mL/100 g b.w.; CO group), or water (0,25 mL/100 g b.w.; group Water). Normal group did not receive any treatment type. The initiation agent was dietilnitrosamine (DEN, 20 mg/100 g b.w.). 2 weeks after gavage, it was applied 3 consecutive doses of 2-acetilaminofluoreno (2-AAF) (2 mg/100 g of b.w.) and it was made a 70% partial hepatectomy, added of 1 dose of 2-AAF (0,5 mg/100 9 b.w.) 4 days after the surgery. In 6 weeks after the initiation, the animals were sacrificed. Results: the macroscopic analysis demonstrated that OA did not alter and UA tended to increase the number of hepatocytes nodules, compared to the CO group. The morphometric analysis of the pre-neoplastic lesions (PNL) positive for glutatione S-transferase placentary form (GST-p), demonstrated that OA and UA did not alter the medium number of persistent LPN, however they reduced the medium number of remodeling LPN, compared to the OM group (p <0,05). OA and UA did not alter the medium area of persistent LPN, but they reduced the medium area of remodeling LPN, compared to the CO group (p <0,05). The triterpenoids did not alter the occupied area of the section for persistent LPN, but they reduced the occupied area cut for remodeling LPN, compared to the CO group (p <0,05). The Water, OM and AU groups showed increase in the plasmatic concentration of cholesterol, compared to the Normal group. OA promoted increase of the expression of the gene that codifies for the HMG-CoA reductase enzyme, compared to the Normal group (p <0,05), and AU promoted increase expression when compared to the Normal, Water, OM and AU groups (p <0,05). OA and UA did not alter the indexes of cellular proliferation (imunoistochemistry for bromodeoxiuridine [BrdU)) in persistent LPN. AU promoted increase (p <0,05) in the cellular proliferation in remodeling LPN when compared to the CO group. OA and UA did not alter the apoptosis in persistent LPN, but they increased the medium number of apoptotics bodies in remodeling LPN (p <0,05). The Adjusted Index Growth (cellular apoptosis/proliferation) of the groups demonstrated that, in persistent LPN, the cellular proliferation has predominance on the apoptosis. In remodeling LPN, the apoptosis has preponderance over the cellular proliferation. The damages in hepatic DNA (method of the \"comet\") were larger in the group OA (p <0,05) and AU (p <0,061), compared to the CO group. The analysis for imunoblot revealed that the RH model increased the expression and the activation of the NF-&#954;B transcription factor (p <0,05). OA and UA increased the expression and the activation of NF-&#954;B, compared to the CO group (p> 0,05). It was observed that the p53 tumor suppresser protein is accumulated in the hepatocytes cytoplasm of 77,2% (Water), 66,5% (CO), 69,6% (OA) and 69,7% (UA) of persistent LPN, and of 22,8% (Water), 33,5% (CO), 30,4% (OA) and 30,3% (UA) of remodeling LPN marked for p53. The bcl-2 anti-apoptotic protein presented increase expression in 78,4% (Water), 72,6% (CO), 73,0% (OA) and 70,4% (UA) of persistent LPN, and of 21,6% (Water), 27,4% (CO), 27,0% (OA) and 29,6% (UA) of remodeling LPN marked for bcl-2. Conclusions: AO and AU did not present chemopreventive activity in the study conditions, but they reduced remodeling PNL. The apoptosis increase and cellular proliferation decrease are involved with the remodeling. The transcription factor NF-&#954;B is involved with the hepatocarcinogenesis. AO and AU increased the expression and the activation of NF-&#954;B. The p53 accumulation in the cytoplasm, as well as the increased expression of bcl-2 is related to the phenotype of persistent PNL.

Les sécrétines de l’hormone de croissance (GHRPs) sont de petits peptides synthétiques capables de stimuler la sécrétion de l’hormone de croissance à partir de l’hypophyse via leur liaison au récepteur de la ghréline GHS-R1a. Le GHRP hexaréline a été utilisé afin d’étudier la distribution tissulaire de GHS-R1a et son effet GH-indépendant. Ainsi, par cette approche, il a été déterminé que l’hexaréline était capable de se lier à un deuxième récepteur identifié comme étant le récepteur scavenger CD36. Ce récepteur possède une multitude de ligands dont les particules oxLDL et les acides gras à longue chaîne. CD36 est généralement reconnu pour son rôle dans l’athérogénèse et sa contribution à la formation de cellules spumeuses suite à l’internalisation des oxLDL dans les macrophages/monocytes. Auparavant, nous avions démontré que le traitement des macrophages avec l’hexaréline menait à l’activation de PPARƔ via sa liaison à GHS-R1a, mais aussi à CD36. De plus, une cascade d’activation impliquant LXRα et les transporteurs ABC provoquait également une augmentation de l’efflux du cholestérol. Une stimulation de la voie du transport inverse du cholestérol vers les particules HDL entraînait donc une diminution de l’engorgement des macrophages de lipides et la formation de cellules spumeuses. Puisque CD36 est exprimé dans de multiples tissus et qu’il est également responsable du captage des acides gras à longue chaîne, nous avons voulu étudier l’impact de l’hexaréline uniquement à travers sa liaison à CD36. Dans le but d’approfondir nos connaissances sur la régulation du métabolisme des lipides par CD36, nous avons choisi des types cellulaires jouant un rôle important dans l’homéostasie lipidique n’exprimant pas GHS-R1a, soient les adipocytes et les hépatocytes. L’ensemble de mes travaux démontre qu’en réponse à son interaction avec l’hexaréline, CD36 a le potentiel de réduire le contenu lipidique des adipocytes et des hépatocytes. Dans les cellules adipeuses, l'hexaréline augmente l’expression de plusieurs gènes impliqués dans la mobilisation et l’oxydation des acides gras, et induit également l’expression des marqueurs thermogéniques PGC-1α et UCP-1. De même, hexaréline augmente l’expression des gènes impliqués dans la biogenèse mitochondriale, un effet accompagné de changements morphologiques des mitochondries; des caractéristiques observées dans les types cellulaires ayant une grande capacité oxydative. Ces résultats démontrent que les adipocytes blancs traités avec hexaréline ont la capacité de se transformer en un phénotype similaire aux adipocytes bruns ayant l’habileté de brûler les acides gras plutôt que de les emmagasiner. Cet effet est également observé dans les tissus adipeux de souris et est dépendant de la présence de CD36. Dans les hépatocytes, nous avons démontré le potentiel de CD36 à moduler le métabolisme du cholestérol. En réponse au traitement des cellules avec hexaréline, une phosphorylation rapide de LKB1 et de l’AMPK est suivie d’une phosphorylation inhibitrice de l’HMG-CoA réductase (HMGR), l’enzyme clé dans la synthèse du cholestérol. De plus, la liaison d'hexaréline à CD36 provoque le recrutement d’insig-2 à HMGR, l’étape d’engagement dans sa dégradation. La dégradation de HMGR par hexaréline semble être dépendante de l’activité de PPARƔ et de l’AMPK. Dans le but d’élucider le mécanisme d’activation par hexaréline, nous avons démontré d’une part que sa liaison à CD36 provoque une déphosphorylation de Erk soulevant ainsi l’inhibition que celui-ci exerce sur PPARƔ et d’autre part, un recrutement de l’AMPK à PGC-1α expliquant ainsi une partie du mécanisme d’activation de PPARƔ par hexaréline. Les résultats générés dans cette thèse ont permis d’élucider de nouveaux mécanismes d’action de CD36 et d'approfondir nos connaissances de son influence dans la régulation du métabolisme des lipides. / Growth hormone releasing peptides (GHRPs) are small synthetic peptides aimed at stimulating GH release from the pituitary through their binding to ghrelin receptor known as growth hormone secretagogue receptor 1a (GHS-R1a). Using the GHRP, hexarelin to study tissue distribution of GHS-R1a and its GH-independent effect, it was observed that hexarelin was capable of binding to a second receptor identified as scavenger receptor CD36. While having multiple ligands, CD36 is mainly known for binding and internalizing oxLDL and long chain fatty acids. CD36 is thought to play a detrimental role in macrophage derived foam cell formation and development of atherosclerosis. Previously, we have shown that in macrophages, expressing both GHS-R1a and CD36, hexarelin promoted an activation of PPARƔ via GHS-R1a but also through its binding to CD36. This activation led to the induction of the LXRα-ABC transporters pathway and an increase in cholesterol efflux, reducing lipid-laden macrophage content. This positive effect on macrophages was reproduced in apolipoprotein E-null mice on a high fat diet treated with hexarelin. A significant reduction in the size of atherosclerotic lesions was observed while similar increases in the expression of PPARƔ, LXRα and ABC transporters occurred in isolated peritoneal macrophages. CD36 also plays a role in fatty acid uptake, and to further investigate the impact of the interaction of hexarelin with CD36, we aimed at evaluating the role of CD36 in regulating lipid metabolism in cells devoid of GHS-R1a such as adipocytes and hepatocytes. In the present thesis, we demonstrated through its interaction with hexarelin, the ability of CD36 to decrease intracellular lipid content in both adipocytes and hepatocytes. In adipocytes, hexarelin was able to increase the expression of several genes involved in fatty acid mobilization, fatty acid oxidation but also to induce the expression of the thermogenic markers, PGC-1α and UCP-1. In addition, hexarelin increased the expression of genes involved in mitochondrial biogenesis which was accompanied by mitochondrial morphological changes in agreement with what is usually seen in highly oxidative cells. In support of these findings, we also observed an increase in the activity of cytochrome c oxidase (a component of the respiratory chain) which could reflect an increase in oxidative phosphorylation. The results generated with cultured white adipocytes suggest the ability of hexarelin to promote changes toward a brown fat-like phenotype which also occurred in vivo and was dependent on the presence of CD36. In hepatocytes, CD36 was capable of regulating cholesterol metabolism by rapidly phosphorylating LKB1 and AMPK which subsequently resulted in the inactivating phosphorylation of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. Hexarelin via CD36 also induced the recruitment of insig-2 to HMGR, the committed step in HMGR degradation while lifting the exerted inhibitory effect of Erk on nuclear receptor PPARƔ activity, and promoting the recruitment of AMPK to PPARƔ coactivator PGC-1α, suggesting an enhanced transcriptional potential of PPARƔ. The results generated during my graduate studies represent unique and novel mechanisms by which CD36 is capable of regulating lipid metabolism.

Les sécrétines de l’hormone de croissance (GHRPs) sont de petits peptides synthétiques capables de stimuler la sécrétion de l’hormone de croissance à partir de l’hypophyse via leur liaison au récepteur de la ghréline GHS-R1a. Le GHRP hexaréline a été utilisé afin d’étudier la distribution tissulaire de GHS-R1a et son effet GH-indépendant. Ainsi, par cette approche, il a été déterminé que l’hexaréline était capable de se lier à un deuxième récepteur identifié comme étant le récepteur scavenger CD36. Ce récepteur possède une multitude de ligands dont les particules oxLDL et les acides gras à longue chaîne. CD36 est généralement reconnu pour son rôle dans l’athérogénèse et sa contribution à la formation de cellules spumeuses suite à l’internalisation des oxLDL dans les macrophages/monocytes. Auparavant, nous avions démontré que le traitement des macrophages avec l’hexaréline menait à l’activation de PPARƔ via sa liaison à GHS-R1a, mais aussi à CD36. De plus, une cascade d’activation impliquant LXRα et les transporteurs ABC provoquait également une augmentation de l’efflux du cholestérol. Une stimulation de la voie du transport inverse du cholestérol vers les particules HDL entraînait donc une diminution de l’engorgement des macrophages de lipides et la formation de cellules spumeuses. Puisque CD36 est exprimé dans de multiples tissus et qu’il est également responsable du captage des acides gras à longue chaîne, nous avons voulu étudier l’impact de l’hexaréline uniquement à travers sa liaison à CD36. Dans le but d’approfondir nos connaissances sur la régulation du métabolisme des lipides par CD36, nous avons choisi des types cellulaires jouant un rôle important dans l’homéostasie lipidique n’exprimant pas GHS-R1a, soient les adipocytes et les hépatocytes. L’ensemble de mes travaux démontre qu’en réponse à son interaction avec l’hexaréline, CD36 a le potentiel de réduire le contenu lipidique des adipocytes et des hépatocytes. Dans les cellules adipeuses, l'hexaréline augmente l’expression de plusieurs gènes impliqués dans la mobilisation et l’oxydation des acides gras, et induit également l’expression des marqueurs thermogéniques PGC-1α et UCP-1. De même, hexaréline augmente l’expression des gènes impliqués dans la biogenèse mitochondriale, un effet accompagné de changements morphologiques des mitochondries; des caractéristiques observées dans les types cellulaires ayant une grande capacité oxydative. Ces résultats démontrent que les adipocytes blancs traités avec hexaréline ont la capacité de se transformer en un phénotype similaire aux adipocytes bruns ayant l’habileté de brûler les acides gras plutôt que de les emmagasiner. Cet effet est également observé dans les tissus adipeux de souris et est dépendant de la présence de CD36. Dans les hépatocytes, nous avons démontré le potentiel de CD36 à moduler le métabolisme du cholestérol. En réponse au traitement des cellules avec hexaréline, une phosphorylation rapide de LKB1 et de l’AMPK est suivie d’une phosphorylation inhibitrice de l’HMG-CoA réductase (HMGR), l’enzyme clé dans la synthèse du cholestérol. De plus, la liaison d'hexaréline à CD36 provoque le recrutement d’insig-2 à HMGR, l’étape d’engagement dans sa dégradation. La dégradation de HMGR par hexaréline semble être dépendante de l’activité de PPARƔ et de l’AMPK. Dans le but d’élucider le mécanisme d’activation par hexaréline, nous avons démontré d’une part que sa liaison à CD36 provoque une déphosphorylation de Erk soulevant ainsi l’inhibition que celui-ci exerce sur PPARƔ et d’autre part, un recrutement de l’AMPK à PGC-1α expliquant ainsi une partie du mécanisme d’activation de PPARƔ par hexaréline. Les résultats générés dans cette thèse ont permis d’élucider de nouveaux mécanismes d’action de CD36 et d'approfondir nos connaissances de son influence dans la régulation du métabolisme des lipides. / Growth hormone releasing peptides (GHRPs) are small synthetic peptides aimed at stimulating GH release from the pituitary through their binding to ghrelin receptor known as growth hormone secretagogue receptor 1a (GHS-R1a). Using the GHRP, hexarelin to study tissue distribution of GHS-R1a and its GH-independent effect, it was observed that hexarelin was capable of binding to a second receptor identified as scavenger receptor CD36. While having multiple ligands, CD36 is mainly known for binding and internalizing oxLDL and long chain fatty acids. CD36 is thought to play a detrimental role in macrophage derived foam cell formation and development of atherosclerosis. Previously, we have shown that in macrophages, expressing both GHS-R1a and CD36, hexarelin promoted an activation of PPARƔ via GHS-R1a but also through its binding to CD36. This activation led to the induction of the LXRα-ABC transporters pathway and an increase in cholesterol efflux, reducing lipid-laden macrophage content. This positive effect on macrophages was reproduced in apolipoprotein E-null mice on a high fat diet treated with hexarelin. A significant reduction in the size of atherosclerotic lesions was observed while similar increases in the expression of PPARƔ, LXRα and ABC transporters occurred in isolated peritoneal macrophages. CD36 also plays a role in fatty acid uptake, and to further investigate the impact of the interaction of hexarelin with CD36, we aimed at evaluating the role of CD36 in regulating lipid metabolism in cells devoid of GHS-R1a such as adipocytes and hepatocytes. In the present thesis, we demonstrated through its interaction with hexarelin, the ability of CD36 to decrease intracellular lipid content in both adipocytes and hepatocytes. In adipocytes, hexarelin was able to increase the expression of several genes involved in fatty acid mobilization, fatty acid oxidation but also to induce the expression of the thermogenic markers, PGC-1α and UCP-1. In addition, hexarelin increased the expression of genes involved in mitochondrial biogenesis which was accompanied by mitochondrial morphological changes in agreement with what is usually seen in highly oxidative cells. In support of these findings, we also observed an increase in the activity of cytochrome c oxidase (a component of the respiratory chain) which could reflect an increase in oxidative phosphorylation. The results generated with cultured white adipocytes suggest the ability of hexarelin to promote changes toward a brown fat-like phenotype which also occurred in vivo and was dependent on the presence of CD36. In hepatocytes, CD36 was capable of regulating cholesterol metabolism by rapidly phosphorylating LKB1 and AMPK which subsequently resulted in the inactivating phosphorylation of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. Hexarelin via CD36 also induced the recruitment of insig-2 to HMGR, the committed step in HMGR degradation while lifting the exerted inhibitory effect of Erk on nuclear receptor PPARƔ activity, and promoting the recruitment of AMPK to PPARƔ coactivator PGC-1α, suggesting an enhanced transcriptional potential of PPARƔ. The results generated during my graduate studies represent unique and novel mechanisms by which CD36 is capable of regulating lipid metabolism.